Sucampo wins FDA approval for glaucoma treatment
Sucampo Pharmaceuticals Inc. has been granted FDA approval of a supplemental new drug application (sNDA) for unoprostone isopropyl for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Sucampo, a Bethesda-based pharmaceutical firm, plans to begin selling the treatment in the first quarter of 2013, which will be marketed under the name of RESCULA.
Open-angle glaucoma is the most common form of glaucoma.
The news was received positively by investors as shares of Sucampo (NASDAQ: SCMP) were sent up 83 cents, 16 percent, to $5.80.
Sucampo Pharmaceuticals wins FDA approval for glaucoma treatment (Washington Business Journal)
Sucampo Pharma Gets SNDA Approval For RESCULA - Quick Facts (RTT News)